Thermo Fisher Scientific Inc. (TMO) 2024 10-K Earnings Analysis
Thermo Fisher Scientific Inc.2024 Earnings Analysis
78/100
Thermo Fisher Scientific Inc.'s FY2024 10-K for the period ended December 31, 2024 is easiest to read through $42.9B of revenue, $6.33B of net income, and $7.27B of free cash flow. M&A Framework, PPD Acquisition, and Scale & Breadth remain the clearest way to understand where the economics come from and why margin durability looks different here than it would at a generic peer. Gross margin was 0.0% and operating margin was 17.1%, so FY2024 does not look like a year bought with weak pricing or loose cost control. The next test is whether management can hold onto today's economics as the business mix and end markets move around it.
Filing analysis
Thermo Fisher Scientific Inc. 2024 10-K Analysis
This page reads Thermo Fisher Scientific Inc.'s 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 78/100, or grade C.
TMO Earnings Quality
The earnings-quality module scores 78/100, with Operating Margin: 17.1%, CF/Net Income: 1.37x. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
TMO Economic Moat Analysis
The moat-strength module scores 85/100, with Scale & Breadth: Life sciences conglomerate, Consumables Annuity: Razor-blade model. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
TMO Free Cash Flow vs Net Income
CF/Net Income: 1.37x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 80/100. For the diagnostic, start with cash flow vs net income.
TMO Key Risks from the Annual Report
The risk module scores 70/100, with Biopharma R&D Cycle: Cycle-sensitive, Goodwill Concentration: 47.1% of assets. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is TMO a High Quality Earnings Stock?
Based on this 2024 filing, TMO needs a closer read before it qualifies as a high-quality earnings candidate: the overall grade is C, and the earnings-quality score is 78/100. This is a research screen, not investment advice.
Read the report first
Understand Thermo Fisher Scientific Inc. first, then decide if it belongs on your watchlist
The TMO score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep TMO with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the TMO report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Per the FY2024 10-K income statement, operating margin of 17.1% reflects the post-pandemic normalization from elevated FY2021-22 COVID testing driven profitability. MD&A attributes the normalized profile to underlying Life Sciences, Analytical Instruments, and Biopharma Services mix dynamics.
Per the FY2024 cash flow statement, OCF of $8.7B is 1.37x net income of $6.33B — the spread reflects acquisition-intangible amortization on the post-M&A asset base plus standard depreciation on manufacturing and laboratory facilities.
Per the FY2024 10-K segment disclosures, revenue is split across Life Sciences Solutions (biosciences, genetic analysis), Analytical Instruments (mass spec, chromatography, electron microscopy), Specialty Diagnostics (clinical, transplant, animal health), and Laboratory Products & Biopharma Services (pharma services including PPD CRO, lab equipment, channel).
Per the FY2024 Laboratory Products & Biopharma Services segment MD&A, PPD (acquired 2021 per the closing press release) provides clinical-research services to biopharma customers. Segment revenue is tied to biotech R&D spending trends referenced in publicly-available biopharma-funding trackers.
FY2024 10-K shows $6.33B of net income on $42.9B of revenue, but the cleaner read is the $8.67B of operating cash flow that turned into $7.27B of free cash flow. M&A Framework and PPD Acquisition help explain why the margin profile stayed where it did instead of collapsing with every demand wobble. Operating margin landed at 17.1%, while capex ran at 3.3% of revenue. Reported profit is converting into cash at a healthy rate, which reduces the odds that the FY2024 result is being flattered by accruals.
Moat Strength
Per the FY2024 10-K business description, Thermo Fisher operates as a broad life sciences tools and services aggregator spanning bench-top instruments, biopharma CRO services, clinical diagnostics, and laboratory consumables. End to end workflow positioning is the principal competitive articulation disclosed in investor-day materials.
Per the FY2024 Life Sciences Solutions and Laboratory Products segment MD&A, the installed base of instruments drives ongoing consumables (reagents, kits, columns, plates) revenue over the equipment service life. The razor blade style annuity is a structural margin support.
Per the FY2024 Analytical Instruments segment disclosures, Thermo Fisher supplies Orbitrap mass spectrometry, Thermo Scientific chromatography, FEI / Thermo electron microscopy, and related analytical platforms. The installed-base ownership across these categories supports research-customer loyalty.
Goodwill of $45.9B on $97B assets equals 47.1% per the FY2024 balance sheet — elevated, reflecting the decade-long M&A accumulation including Life Technologies (2014), Patheon (2017), FEI (2016), PPD (2021 per the $17.4B closing press release), and Olink (2024 per the closing announcement).
The competitive position starts with M&A Framework and PPD Acquisition, not with a vague appeal to scale. Scale & Breadth and Biopharma R&D Cycle matter because they deepen switching friction, expand installed-base economics, or widen route to market reach. FY2024 ROE was 12.8%, but the more important check is that cash generation and margins still support the operating story. That does not make the business immune; it means the next competitor has to overcome a functioning operating system rather than just a familiar name.
Capital Allocation
Per the FY2024 cash flow statement, FCF of $7.3B (OCF $8.7B minus capex $1.4B) supports the dividend, share repurchase, and bolt-on M&A including the 2024 Olink acquisition per the closing announcement.
Per successive 10-K M&A disclosures and closing press releases, Thermo Fisher has executed a steady cadence of acquisitions over the past decade — Life Technologies (2014), FEI (2016), Patheon (2017), PPD (2021 per the $17.4B announcement), and Olink (2024). M&A is publicly framed as a primary growth and capability expansion vector.
Per the FY2024 proxy and capital-return disclosures, Thermo Fisher maintains a regular dividend and opportunistic share repurchases. Relative to M&A spending, shareholder direct returns are disciplined as described in the waterfall.
Per the FY2024 balance sheet, interest-bearing debt of $31.1B is largely the result of the 2021 PPD-acquisition financing per the company's concurrent bond-offering press releases. Deleveraging has progressed per subsequent investor-day communications.
$7.27B of free cash flow is the starting point for the capital-allocation discussion, because it defines how much room management actually had after funding the business. Capex intensity is light at 3.3% of revenue, so the real allocation decision is what management does with the cash left after maintaining the platform. $4.01B of cash against $31.1B of debt means the balance sheet depends on steady cash generation rather than on idle liquidity. The capital-return file is split between the dividend and share repurchases, with room for both as long as cash generation stays near the current level.
Key Risks
Per the FY2024 Laboratory Products & Biopharma Services segment MD&A, PPD revenue tracks biopharma-industry R&D spending. Biotech-funding cycles — disclosed in trade-press funding trackers and the quarterly BIO funding reports — affect CRO demand.
Per the FY2024 balance sheet, $45.9B goodwill concentrates impairment risk on the reporting units carrying the largest allocated purchase-price allocations (notably the PPD, Patheon, and Life Technologies integrations). Impairment testing follows the disclosed policy.
Per the FY2024 Life Sciences Solutions segment MD&A, academic and government research institution end-market demand depends on NIH grant cycles and equivalent international research-funding trajectories disclosed in public budget documents.
Per the FY2024 Risk Factors, China-bioscience end-market demand has shown cyclical softness. Geographic-revenue disclosures in the 10-K segment footnote track the exposure; US-China trade-policy developments disclosed via USTR communications are a secondary consideration.
The risk section is better read as a set of operating tradeoffs than as one binary red flag. Pressure in one part of the model can travel into margins and cash conversion faster than the headline score suggests. Goodwill is 47.1% of assets, so portfolio execution and acquisition discipline remain part of the risk discussion. The next test is whether management can hold onto today's economics as the business mix and end markets move around it.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.